Everolimus Personalized Therapy: Second Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Autor: Masuda S; Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Japan., Lemaitre F; Univ Rennes, CHU Rennes, Inserm, EHESP, IRSET-UMR S 1085, Rennes, France.; INSERM, Centre d'Investigation Clinique 1414, Rennes, France.; FHU SUPPORT, Rennes, France., Barten MJ; Department of Cardiac- and Vascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany., Bergan S; Department of Pharmacology, Oslo University Hospital and Department of Pharmacy, University of Oslo, Norway., Shipkova M; Bioscientia Healthcare, Ingelheim, Germany., van Gelder T; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Vinks S; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.; NDA Partners, A Propharma Group Company, Washington District of Columbia., Wieland E; Bioscientia Healthcare, Ingelheim, Germany., Bornemann-Kolatzki K; Chronix Biomedical GmbH, Göttingen, Germany., Brunet M; Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain., de Winter B; Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands., Dieterlen MT; Laboratory Management Research Laboratory, Cardiac Surgery Clinic, Heart Center Leipzig GmbH, University Hospital, Leipzig, Germany., Elens L; Integrated Pharmacometrics, Pharmacogenetic and Pharmacokinetics Research Group (PMGK) Louvain Drug for Research Institute (LDRI), Catholic University of Louvain, (UCLouvain), Brussels, Belgium., Ito T; Department of Organ Transplant Surgery; Fujita Health University School of Medicine, Toyoake Aichi, Japan., Johnson-Davis K; University of Utah Health Sciences Center and ARUP Laboratories, Salt Lake City, Utah., Kunicki PK; Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland., Lawson R; University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France., Lloberas N; Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain., Marquet P; University of Limoges, Inserm U1248, Pharmacology & Transplantation, Limoges, France.; Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, France., Millan O; Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain., Mizuno T; Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio., Moes DJAR; Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands., Noceti O; National Center for Liver Transplantation and Liver Diseases, Army Forces Hospital, Montevideo, Uruguay., Oellerich M; Department of Clinical Pharmacology, University Medical Center Göttingen, Georg-August-University Göttingen, Göttingen, Germany., Pattanaik S; Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India., Pawinski T; Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Faculty of Pharmacy, Medical University of Warsaw, Warsaw, Poland., Seger C; Labordiagnostic St. Gallen West AG, St. Gallen, Switzerland., van Schaik R; Department of Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, the Netherlands., Venkataramanan R; Department of Pharmaceutical Sciences, School of Pharmacy and Department of Pathology, Starzl Transplantation Institute, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania., Walson P; University Medical School, Göttingen, Germany., Woillard JB; Department of Pharmacology, Toxicology and Pharmacovigilance, CHU de Limoges, Limoges, France; and., Langman LJ; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.

Publikováno v: Therapeutic drug monitoring [Ther Drug Monit] 2024 Sep 25. Date of Electronic Publication: 2024 Sep 25.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased transcriptional activity of the CYP3A4*1B promoter variant

Autor: Amirimani, B., Ning, B., Deitz, A.C., Weber, B.L., Kadlubar, F.F.

Publikováno v: Environmental and Molecular Mutagenesis; 2003, Vol. 42 Issue: 4 p299-305, 7p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

Autor: Amirimani, B, Walker, AH, Weber, BL, Rebbeck, TR

Publikováno v: JNCI: Journal of the National Cancer Institute; 09/15/99, Vol. 91 Issue 18, p1588-1590, 3p